Cartesian Therapeutics (RNAC) Enterprise Value: 2015-2025
Historic Enterprise Value for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $122.4 million.
- Cartesian Therapeutics' Enterprise Value fell 29.24% to $122.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.0 million, marking a year-over-year decrease of 355.48%. This contributed to the annual value of $242.6 million for FY2024, which is 706.24% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Enterprise Value of $122.4 million as of Q3 2025, which was up 11.90% from $109.3 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Enterprise Value peaked at $393.4 million during Q2 2024, and registered a low of $1.8 million during Q1 2024.
- Over the past 3 years, Cartesian Therapeutics' median Enterprise Value value was $109.3 million (recorded in 2025), while the average stood at $133.1 million.
- As far as peak fluctuations go, Cartesian Therapeutics' Enterprise Value plummeted by 97.88% in 2024, and later soared by 8,610.48% in 2025.
- Cartesian Therapeutics' Enterprise Value (Quarterly) stood at $252.2 million in 2021, then tumbled by 84.81% to $38.3 million in 2022, then decreased by 21.49% to $30.1 million in 2023, then soared by 706.24% to $242.6 million in 2024, then fell by 29.24% to $122.4 million in 2025.
- Its last three reported values are $122.4 million in Q3 2025, $109.3 million for Q2 2025, and $161.0 million during Q1 2025.